Get started
Author

Yaron Pereg

Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage
2005 · Yaron Pereg, Dganit Shkedy, et al. · Proceedings of the National Academy of Sciences · 181
ATM-Mediated Phosphorylations Inhibit Mdmx/Mdm2 Stabilization by HAUSP in Favor of p53 Activation
2005 · Erik Meulmeester, Yaron Pereg, et al. · Cell Cycle · 167
PDF
DNA Damage-Induced Phosphorylation of MdmX at Serine 367 Activates p53 by Targeting MdmX for Mdm2-Dependent Degradation
2005 · Koji Okamoto, Kenji Kashima, et al. · Molecular and Cellular Biology · 129
Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A
2010 · Yaron Pereg, Bob Y. Liu, et al. · Nature Cell Biology · 125
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
2017 · M Abraham, S Klein, et al. · Leukemia · 111
Dual targeting of the protein disulfide isomerase RB60 to the chloroplast and the endoplasmic reticulum
2005 · Alexander Levitan, Tova Trebitsh, et al. · Proceedings of the National Academy of Sciences · 99
PDF
Differential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage
2006 · Yaron Pereg, Suzanne Lam, et al. · Molecular and Cellular Biology · 93
Nuclear Ataxia-Telangiectasia Mutated (ATM) Mediates the Cellular Response to DNA Double Strand Breaks in Human Neuron-like Cells
2006 · Sharon Biton, Inbal Dar, et al. · Journal of Biological Chemistry · 74
CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
2017 · Shiri Klein, Michal Abraham, et al. · Cancer Research · 56
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
2017 · Michal Abraham, Yaron Pereg, et al. · Clinical Cancer Research · 52
ATM-mediated response to DNA double strand breaks in human neurons derived from stem cells
2006 · Sharon Biton, Michal Gropp, et al. · DNA repair · 47
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
2020 · Gautam Borthakur, Yishai Ofran, et al. · Cancer · 43
PDF
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity
2022 · Ewa Cendrowicz, Lisa Jacob, et al. · Journal of Experimental & Clinical Cancer Research · 27
PDF
The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia
2015 · Gautam Borthakur, Yishai Ofran, et al. · Blood · 18
BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial
2014 · Gautam Borthakur, Arnon Nagler, et al. · Blood · 14
Abstract A076: DSP107—a novel SIRPα-4-1BBL dual signaling protein (DSP) for cancer immunotherapy
2019 · Yosi M. Gozlan, Susan Hilgendorf, et al. · Cancer Immunology Research · 10
DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses
2020 · Ewa Cendrowicz, Lisa Jacob, et al. · Blood · 8
The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia
2016 · Gautam Borthakur, Martin S. Tallman, et al. · Blood · 5
The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells
2013 · Sigal Tavor, Ido Weiss, et al. · Blood · 5
Effect of BL-8040, high-affinity CXCR4 antagonist, on T-cell infiltration, tumor growth, and synergy with immunomodulatory agents.
2017 · Michal Abraham, Inbal Mishalian, et al. · Journal of Clinical Oncology · 3
Selective Targeting of Immune Checkpoints HLA‐G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity
2026 · Lisa J. Jacob, Liat Tamir, et al. · Advanced Science · 2
PDF
DSP502 Combines Dual Inhibition of PD-L1 and PVR to Trigger Anticancer Immune Responses
2026 · Vinicio A. Melo Gallegos, Shirley Greenwald, et al. · Molecular Cancer Therapeutics · 1
Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients
2016 · Gautam Borthakur, Martin Tallman, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Table S4 from DSP502 Combines Dual Inhibition of PD-L1 and PVR to Trigger Anticancer Immune Responses
2026 · Vinicio A. Melo Gallegos, Shirley Greenwald, et al.
Figure S2 from DSP502 Combines Dual Inhibition of PD-L1 and PVR to Trigger Anticancer Immune Responses
2026 · Vinicio A. Melo Gallegos, Shirley Greenwald, et al.
Works count: 67
Citation count: 1,271
H-index: 14
I10-index: 16
Year
Topic
Type